Abstract: An antibiotic agent produced by the cultivation of Zalerion arboricola which is a cyclic lipopeptide with very high activity against human pathogens and of very low mammalian toxicity is described. Its production and isolation are also described.
Type:
Grant
Filed:
August 19, 1991
Date of Patent:
April 13, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Robert E. Schwartz, Jerrold M. Liesch, Raymond F. White, Otto D. Hensens, Henry Joshua, Dennis M. Schmatz
Abstract: A mixture of derivatives of 2-amino-3,4,5,14-tetrahydroxy-6-eicosenoic acid has been isolated from a culture medium after cultivation of microorganisms belonging to the genus Aspergillus. The compounds are useful as antifungal agents.
Abstract: An antibiotic agent produced by the cultivation of Zalerion arboricola which is a cyclic lipopeptide with very high activity against human pathogens and of very low mammalian toxicity is described. Its production and isolation are also described.
Abstract: Certain Factor XIIIa inhibitor compounds have been discovered which have been found to be useful in the lysis of blood clots and thus adaptable for administration in thrombolytic therapy either alone or together with plasminogen activator.
Type:
Grant
Filed:
April 2, 1990
Date of Patent:
February 23, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Joseph G. Atkinson, David A. Claremon, John J. Baldwin, Paul A. Friedman, David C. Remy, Andrew M. Stern
Abstract: Certain Factor XIIIa inhibitor compounds have been discovered which have been found to be useful in the lysis of blood clots and thus adaptable for administration in thrombolytic therapy either alone or together with plasminogen activator.
Type:
Grant
Filed:
April 2, 1990
Date of Patent:
February 9, 1993
Assignee:
Merck & Co., Inc.
Inventors:
John J. Baldwin, Paul A. Friedman, Andrew M. Stern
Abstract: New antibacterial spirocyclic 6-amido carbapenems of the structural formulas: ##STR1## wherein R.sup.1 is hydrogen, C.sub.1-8 substituted or unsubstituted alkyl, or C.sub.6-10 substituted or unsubstituted aryl; R.sup.5 is hydrogen or a protecting group for alcohol; R.sup.6 is hydrogen or a protecting group for amido nitrogen; R.sup.7 is hydrogen or a protecting group for amido nitrogen; and R.sup.8 is hydroxy, hydrogen, C.sub.1-8 substituted or unsubstituted thioalkyl, C.sub.6-10 substituted or unsubstituted thioaryl, 5 or 6 membered, substituted or unsubstituted thioheteroaryl; and a process for their synthesis through novel spirocyclic 4-amido azetidinones are disclosed.
Type:
Grant
Filed:
July 9, 1991
Date of Patent:
February 2, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Mark L. Greenlee, Thomas N. Salzmann, Frank P. DiNinno
Abstract: Monofluorophosphate salts, especially sodium monofluorophosphate (Na.sub.2 PO.sub.3 F), when added to various industrial water systems in concentrations between 0.1 mg/L and 50 mg/L, significantly reduce the amount of calcium carbonate scale which is formed on heat exchange and other metallic surfaces of such systems.Monofluorophosphate salts, especially sodium monofluorophosphate, when added to various water systems in concentrations between 0.1 mg/L and 50 mg/L also stabilizes soluble manganese ion and its reaction products, i.e., primarily MnO.sub.2, in desirable forms and reduced particle sizes.Monofluorophosphate salts, especially sodium monofluorophosphate, when added to various water systems in concentrations between 1 mg/L and 500 mg/L also stabilizes soluble iron ion and its reaction products, i.e., primarily Fe.sub.2 O.sub.3.
Abstract: A method for the treatment of Pneumocystis carinii, the causative agent of pneumonia of particular severity to immune compromised patients such as those with acquired immune deficiency syndrome (AIDS), by administering a lipophilic cyclohexapeptide compound of the general formula ##STR1## wherein the R groups are fully defined in the text, is described. Compositions suitable for the treatment of P. carinii are also disclosed.
Abstract: Female prenatal, neonatal and postnatal animals are treated with compositions containing steroid biosynthesis inhibitors or antagonists which prevents the conversion of androgens to estrogens. The compositions are useful for improving growth and feed efficiency.
Type:
Grant
Filed:
October 5, 1990
Date of Patent:
November 10, 1992
Assignee:
Merck & Co., Inc.
Inventors:
Alexander Elbrecht, Yi-Tien Yang, Roy G. Smith